Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases.
作者信息
Korobelnik Jean-François, Lanzetta Paolo, Wykoff Charles C, Wong Tien Y, Zhang Xin, Morgan-Warren Peter, Fitzpatrick Scott, Leal Sergio, Brunck Lynne, Hasanbasic Zoran, Chu Karen W, Reed Kimberly, Sivaprasad Sobha
机构信息
CHU Bordeaux, Service d'ophtalmologie, Bordeaux, France.
University of Bordeaux, INSERM, BPH, UMR1219, Bordeaux, France.
出版信息
Eye (Lond). 2024 Dec;38(17):3218-3221. doi: 10.1038/s41433-024-03312-w. Epub 2024 Aug 31.
Abstract
摘要
相似文献
1
Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases.8毫克阿柏西普实现持续疾病控制：视网膜新生血管疾病管理的新标杆
Eye (Lond). 2024 Dec;38(17):3218-3221. doi: 10.1038/s41433-024-03312-w. Epub 2024 Aug 31.
2
Aflibercept for neovascular age-related macular degeneration.阿柏西普用于治疗新生血管性年龄相关性黄斑变性。
Cochrane Database Syst Rev. 2016 Feb 8;2(2):CD011346. doi: 10.1002/14651858.CD011346.pub2.
3
Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials.抗 VEGF 药物治疗新生血管性年龄相关性黄斑变性的液体管理：HAWK 和 HARRIER 三期临床试验分析。
Ophthalmologica. 2022;245(5):403-412. doi: 10.1159/000524096. Epub 2022 Apr 25.
4
Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab.抗血管内皮生长因子药物治疗抵抗的新生血管性年龄相关性黄斑变性患者玻璃体内注射阿柏西普后视网膜色素上皮脱离的快速消退。
Eye (Lond). 2013 May;27(5):663-7; quiz 668. doi: 10.1038/eye.2013.31. Epub 2013 Apr 5.
5
Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept.用于治疗视网膜疾病的融合蛋白：阿柏西普、阿柏西普眼内注射溶液和康柏西普。
Int J Retina Vitreous. 2016 Feb 1;2:3. doi: 10.1186/s40942-016-0026-y. eCollection 2016.
6
Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study.在一项前瞻性病例系列研究（EVEN研究）中，对阿柏西普治疗与新生血管性年龄相关性黄斑变性相关的黄斑下血管化色素上皮脱离进行细致的多模式分析。
Am J Ophthalmol Case Rep. 2020 Sep 18;20:100916. doi: 10.1016/j.ajoc.2020.100916. eCollection 2020 Dec.
7
Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report.玻璃体内注射8毫克阿柏西普治疗难治性新生血管性年龄相关性黄斑变性后的眼内炎症：一例报告
BMC Ophthalmol. 2025 Jan 23;25(1):42. doi: 10.1186/s12886-024-03827-6.
8
Efficacy of Aflibercept as initial treatment for neovascular age-related macular degeneration in an Iraqi patient sample.阿柏西普作为初始治疗药物在伊拉克患者样本中对新生血管性年龄相关性黄斑变性的疗效。
J Med Life. 2023 Feb;16(2):235-243. doi: 10.25122/jml-2022-0356.
9
Efficacy, Safety, and Injection Frequency with Novel Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Comparison with Existing Anti-VEGF Regimens Using a Bayesian Network Meta-Analysis.新型8毫克阿柏西普治疗新生血管性年龄相关性黄斑变性的疗效、安全性及注射频率：使用贝叶斯网络荟萃分析与现有抗血管内皮生长因子治疗方案的比较
Ophthalmol Ther. 2025 Apr;14(4):733-753. doi: 10.1007/s40123-025-01098-y. Epub 2025 Feb 24.
10
MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.MERLIN：布罗鲁单抗治疗新生血管性年龄相关性黄斑变性和持续性视网膜积液患者的两年结果。
Ophthalmology. 2025 Feb;132(2):131-140. doi: 10.1016/j.ophtha.2024.08.022. Epub 2024 Sep 7.
引用本文的文献
1
Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom.英国湿性年龄相关性黄斑变性患者换用8毫克阿柏西普的早期真实世界疗效
Life (Basel). 2025 Jun 2;15(6):903. doi: 10.3390/life15060903.
2
Early real-world outcomes of intravitreal aflibercept 8 mg in treatment-Naïve neovascular AMD: AI-assisted fluid volume analysis.玻璃体内注射8毫克阿柏西普治疗初治新生血管性年龄相关性黄斑变性的早期真实世界疗效：人工智能辅助的液体体积分析
Int J Retina Vitreous. 2025 Apr 8;11(1):42. doi: 10.1186/s40942-025-00665-6.
本文引用的文献
1
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.玻璃体内注射阿柏西普 8mg 治疗糖尿病黄斑水肿（PHOTON）：一项随机、双盲、非劣效、2/3 期临床试验的 48 周结果。
Lancet. 2024 Mar 23;403(10432):1153-1163. doi: 10.1016/S0140-6736(23)02577-1. Epub 2024 Mar 7.
2
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.玻璃体内注射阿柏西普 8mg 治疗新生血管性年龄相关性黄斑变性（PULSAR）：一项随机、双盲、非劣效性、3 期临床试验的 48 周结果。
Lancet. 2024 Mar 23;403(10432):1141-1152. doi: 10.1016/S0140-6736(24)00063-1. Epub 2024 Mar 7.
3
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.高剂量玻璃体内注射阿柏西普，8 毫克，治疗新生血管性年龄相关性黄斑变性患者的疗效：CANDELA 随机临床试验的 2 期研究。
JAMA Ophthalmol. 2023 Sep 1;141(9):834-842. doi: 10.1001/jamaophthalmol.2023.2421.
4
Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose.延长血管内皮生长因子（VEGF）抑制作用增加玻璃体内阿柏西普剂量的药代动力学和药效学原理。
Pharmaceutics. 2023 May 6;15(5):1416. doi: 10.3390/pharmaceutics15051416.
5
Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options.新生血管性年龄相关性黄斑变性（nAMD）：新兴治疗选择综述
Clin Ophthalmol. 2022 Mar 25;16:917-933. doi: 10.2147/OPTH.S231913. eCollection 2022.
6
Retinal vein occlusion (RVO) guideline: executive summary.视网膜静脉阻塞（RVO）指南：执行摘要。
Eye (Lond). 2022 May;36(5):909-912. doi: 10.1038/s41433-022-02007-4. Epub 2022 Mar 17.
7
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.玻璃体腔内 faricimab 每 16 周治疗新生血管性年龄相关性黄斑变性的疗效、持久性和安全性（TENAYA 和 LUCERNE）：两项随机、双盲、3 期、非劣效性试验。
Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24.
8
Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD.抗 VEGF 治疗中 nAMD 眼黄斑区液体积聚波动对视力的影响。
Eye (Lond). 2021 Nov;35(11):2983-2990. doi: 10.1038/s41433-020-01354-4. Epub 2021 Jan 7.
9
Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration: A Mixed-Methods Systematic Review.抗 VEGF 药物治疗新生血管性年龄相关性黄斑变性的不依从或不持续治疗：一项混合方法系统评价。
Ophthalmology. 2021 Feb;128(2):234-247. doi: 10.1016/j.ophtha.2020.07.060. Epub 2020 Aug 5.
10
Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.真实世界中玻璃体内注射阿柏西普治疗糖尿病黄斑水肿：36 个月视力和解剖学结局。
Eur J Ophthalmol. 2021 May;31(3):1201-1207. doi: 10.1177/1120672120925034. Epub 2020 May 19.
Zotero 插件